Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Globus Medical, driven by higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.74 per share, reflecting a +2.8% change year-over-year, with revenues projected at $628.32 million, up 3.6% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Globus Medical is higher than the consensus estimate, resulting in a positive Earnings ESP of +2.40%, indicating a bullish sentiment among analysts [10]. Historical Performance - Globus Medical has a strong track record, having beaten consensus EPS estimates in the last four quarters, including a +10.53% surprise in the most recent quarter [12][13]. Stock Ranking - The company currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [11]. Conclusion - Globus Medical is positioned as a compelling candidate for an earnings beat, but investors should consider additional factors beyond earnings expectations when making investment decisions [16].

The market expects HubSpot (HUBS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...

Core Viewpoint - ImmunityBio (IBRX) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a quarterly loss of $0.12 per share, reflecting a 40% improvement from the previous year, and revenues expected to reach $15.69 million, a staggering increase of 39,125% from the same quarter last year [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the upcoming report, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised down by 1.45% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for ImmunityBio is lower than the consensus estimate, resulting in an Earnings ESP of -2.85%, suggesting a bearish outlook [10][11]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [8]. Historical Performance - In the last reported quarter, ImmunityBio was expected to post a loss of $0.26 per share but actually reported a loss of $0.15, resulting in a positive surprise of 42.31% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [13]. Comparative Industry Analysis - Pacira (PCRX), another player in the biomedical and genetics industry, is expected to report earnings of $0.57 per share, reflecting an 8.1% decline year-over-year, with revenues projected at $174.96 million, a 4.7% increase [17]. - Pacira's consensus EPS estimate has remained unchanged over the last 30 days, but it has an Earnings ESP of 34.51%, indicating a strong likelihood of beating the consensus estimate [18].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Golden Entertainment despite lower revenues, with a focus on how actual results will compare to estimates [1][2]. Earnings Expectations - Golden Entertainment is expected to report quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +127%, while revenues are projected to be $162.32 million, down 6.7% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.54% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates a negative Earnings ESP of -41.85% for Golden Entertainment, suggesting analysts have become bearish on the company's earnings outlook [11][10]. Historical Performance - In the last reported quarter, Golden Entertainment was expected to post earnings of $0.22 per share but only achieved $0.10, resulting in a surprise of -54.55%. Over the last four quarters, the company has only beaten consensus EPS estimates once [12][13]. Investment Considerations - Despite the negative indicators, the potential for stock movement is influenced by various factors beyond earnings results, including unforeseen catalysts and overall market conditions [14][16].

Company Overview - Inter & Co. Inc. (INTR) is expected to report a year-over-year increase in earnings, with a projected EPS of $0.12, reflecting a change of +33.3% [3] - Revenues are anticipated to reach $327.02 million, which is a 15.6% increase from the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent changes in analyst views [10] Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8] - Inter & Co. Inc. currently holds a Zacks Rank of 2, making it challenging to predict an earnings beat conclusively [11] Historical Performance - In the last reported quarter, Inter & Co. Inc. exceeded the consensus EPS estimate of $0.10 by delivering $0.11, resulting in a surprise of +10% [12] - Over the past four quarters, the company has beaten consensus EPS estimates three times [13] Industry Context - In the Zacks Financial - Miscellaneous Services industry, HA Sustainable Infrastructure Capital (HASI) is expected to post earnings of $0.64 per share, indicating a year-over-year decline of -5.9% [17] - HASI's revenue is projected to be $33 million, down 21.3% from the previous year [17] - The consensus EPS estimate for HASI has been revised 0.8% higher in the last 30 days, but a lower Most Accurate Estimate results in an Earnings ESP of -3.91% [18]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Century Therapeutics, Inc. due to higher revenues, but actual results compared to estimates will significantly influence the stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.31 per share, reflecting a year-over-year change of +31.1% [3]. - Revenues are projected to be $45.52 million, representing a substantial increase of 5193% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.86% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Century Therapeutics is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -30.43% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from consensus estimates, with positive readings being more predictive of earnings beats [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have shown a nearly 70% success rate in delivering positive surprises [8]. Historical Performance - In the last reported quarter, Century Therapeutics was expected to post a loss of $0.45 per share but delivered a loss of $0.43, resulting in a surprise of +4.44% [12]. - The company has beaten consensus EPS estimates in the last four quarters [13]. Conclusion - Century Therapeutics does not currently appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [16].

Core Viewpoint - Ironwood Pharmaceuticals (IRWD) is anticipated to report a year-over-year decline in earnings due to lower revenues for the quarter ended March 2025, with the consensus outlook indicating a significant impact on its near-term stock price [1][3]. Earnings Expectations - The consensus EPS estimate for Ironwood is a loss of $0.05 per share, reflecting a year-over-year change of -150% [3]. - Expected revenues are projected at $59.45 million, which is a decrease of 20.6% compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 42.86%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Ironwood is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -121.05% [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictive power for positive readings [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically produced a positive surprise nearly 70% of the time [8]. Historical Performance - Ironwood has not been able to beat consensus EPS estimates in any of the last four quarters, with a notable surprise of -80% in the last reported quarter [12][13]. Conclusion - Ironwood does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding this stock ahead of its earnings release [16].

The market expects Kenvue (KVUE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 8, 2025, might help the stock move higher if these key numbers are better than ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Nektar Therapeutics (NKTR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the ...

Company Overview - Nomad Foods (NOMD) is expected to report flat earnings of $0.40 per share for the quarter ended March 2025, which represents no change from the year-ago quarter [3] - Revenues are anticipated to be $842.53 million, reflecting a 1% decrease from the previous year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could influence stock movement depending on whether the results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 4.85% higher over the last 30 days, indicating a positive reassessment by analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Nomad Foods is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +3.80% [10][11] - The company currently holds a Zacks Rank of 1 (Strong Buy), suggesting a high likelihood of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Nomad Foods had an earnings surprise of +15.38%, posting earnings of $0.45 per share against an expectation of $0.39 [12] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [13] Industry Context - Hain Celestial (HAIN), a competitor in the Zacks Food - Miscellaneous industry, is expected to report earnings of $0.12 per share, indicating a year-over-year decline of 7.7% [17] - Hain Celestial's revenues are projected to be $411.32 million, down 6.2% from the previous year [17]